Levocetirizine

ApprovedCompleted

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Rhinitis, Allergic, Perennial

Conditions

Rhinitis, Allergic, Perennial

Trial Timeline

Mar 1, 2005 → Jun 1, 2006

NCT ID

NCT00160680

About Levocetirizine

Levocetirizine is a approved stage product being developed by UCB for Rhinitis, Allergic, Perennial. The current trial status is completed. This product is registered under clinical trial identifier NCT00160680. Target conditions include Rhinitis, Allergic, Perennial.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00315523	Phase 3	Completed	Jul 1, 2006	Oct 1, 2006	Rhinitis, Allergic, Seasonal
NCT00160537	Approved	Completed	May 1, 2005	Jul 1, 2005	Seasonal Allergic Rhinitis
NCT00160589	Approved	Completed	Apr 1, 2005	Sep 1, 2005	Rhinitis, Allergic, Perennial
NCT00160680	Approved	Completed	Mar 1, 2005	Jun 1, 2006	Rhinitis, Allergic, Perennial
NCT00521170	Phase 1	Completed	Nov 1, 2004	Jan 1, 2005	Allergy
NCT00160563	Phase 3	Terminated	Jun 1, 2004	Mar 1, 2006	Asthma

Competing Products

20 competing products in Rhinitis, Allergic, Perennial

See all competitors

Product	Company	Stage	Hype Score
LY3650150 + Placebo + Standard therapy for INCS	Eli Lilly	Phase 3	77
Bilastine + Desloratadine + Placebo	Yuhan	Phase 3	77
ASP4070 + Placebo	Astellas Pharma	Phase 2	52
S-555739 Dose 1 + S-555739 Dose 2 + Cetirizine HCl Dose 1 + S-555739 placebo + Cetirizine HCl placebo	Shionogi	Phase 2	52
Cetirizine + High dose ONO-4053 + Low dose ONO-4053 + Placebo	Ono Pharmaceutical	Phase 2	52
placebo, isotonic ciclesonide, hypotonic ciclesonide	Sumitomo Pharma	Approved	85
ciclesonide nasal aerosol + ciclesonide nasal spray	Sumitomo Pharma	Approved	85
ciclesonide hydrofluoroalkane (HFA) nasal aerosol + mometasone nasal inhalation	Sumitomo Pharma	Phase 3	77
Ciclesonide nasal aerosol 37 mcg + ciclesonide nasal aerosol 74 mcg + Placebo	Sumitomo Pharma	Phase 3	77
ciclesonide nasal aerosol + mometasone Aqueous (AQ) nasal spray	Sumitomo Pharma	Phase 1	33
ciclesonide + mometasone	Sumitomo Pharma	Phase 3	77
DSP-3025 + Placebo	Sumitomo Pharma	Phase 1	33
ciclesonide nasal aerosol + Placebo	Sumitomo Pharma	Phase 3	77
Ciclesonide HFA 80 mcg + Ciclesonide HFA 160 mcg + Placebo	Sumitomo Pharma	Phase 3	77
Ciclesonide HFA Nasal Aerosol 320 mcg + Ciclesonide HFA Nasal Aerosol 160 mcg + HFA Nasal Aerosol placebo + Ciclesonide Aqueous Nasal Spray 200 mcg + AQ Nasal Spray Placebo + Placebo plus Dexamethasone HFA + Placebo AQ plus Dexamethasone 6 mg	Sumitomo Pharma	Phase 3	77
Ciclesonide nasal aerosol 37 mcg + ciclesonide nasal aerosol 74 mcg + Placebo	Sumitomo Pharma	Phase 3	77
80 mcg Ciclesonide + 160 mcg Ciclesonide + Placebo	Sumitomo Pharma	Phase 3	77
ciclesonide HFA 160 μg	Sumitomo Pharma	Phase 3	77
Ciclesonide HFA 160 μg + Ciclesonide HFA 80 μg + Placebo	Sumitomo Pharma	Phase 3	77
GSP 301-1 NS (QD) + GSP 301-2 NS (BID) + GSP 301 Placebo NS + Olopatadine HCl-1 NS (QD) + Olopatadine HCl-2 NS (BID) + Mometasone Furoate-1 NS (QD) + Mometasone Furoate-2 NS (BID)	Glenmark Pharmaceuticals	Phase 2	52

Other Products from UCB

LevetiracetamApproved

Parcopa + carbidopa-levodopa (Sinemet)Approved

RotigotineApproved

Levetiracetam + OxcarbazepineApproved

Niravam + SSRI/SNRIApproved